跳至主要内容
临床试验/NCT07573059
NCT07573059招募中不适用

A Multicenter, Prospective Study Assessing the Safety of Loargys Arginine Test System for Determining Arginine in Loargys-treated Patients

Immedica Pharma US Inc1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年4月17日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
1

研究概览

简要总结

Arginase 1 deficiency (ARG1-D) is a rare condition in which the body cannot properly break down a substance called arginine. This leads to high levels of arginine and related substances in the blood, which can cause serious health problems and reduce quality of life.

Loargys is a new treatment designed to lower arginine levels in people with ARG1-D. It works by providing a modified version of a natural enzyme that breaks down arginine in the blood. The dose of Loargys is adjusted for each patient based on their arginine levels.

Because Loargys continues to break down arginine even after a blood sample has been taken, to ensure accurate results, a special substance (called nor-NOHA) is added to the blood collection tubes to stop this process after the sample is taken. The arginine levels are then measured using a standard laboratory test.

The Loargys Arginine Test System used in this study includes both the special blood collection tubes and the laboratory test used to measure arginine.

The purpose of this study is to evaluate the safety of this test system when used to measure arginine levels in patients receiving Loargys.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
0 Years 至 100 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant receiving treatment with commercialized Loargys for ARG1-D
  • Participant is willing to sign the Informed Consent Form

排除标准

  • 未提供

研究者

发起方
Immedica Pharma US Inc
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验